1. Medtech Insight
  2. >>Device Area
  3. >>Diagnostics

Advocates Ask Medicare To Reverse Transplant Patient Test Payment Policy

 
• By Elizabeth Orr

A recent Capitol Hill event drew speakers such as Newt Gingrich, Sen. Kirsten Gillibrand, and musician Al B. Sure to protest a Medicare contractor’s decision to restrict coverage of blood tests used to detect early signs of rejection or organ damage in transplant patients.

Activists gather at the Capitol ahead of a rally for transplant patient advocacy group Honor the Gift.
• Source: Honor the Gift

It might seem that few causes could attract advocates as disparate as Sen. Kirsten Gillibrand (D-NY), former Republican Speaker of the House Newt Gingrich, civil rights activist Al Sharpton and new jack swing legend Al B. Sure.

One of the few is organ transplant, as the four were among the speakers at a 5 December rally to encourage Medicare to cover blood tests that detect early signs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diagnostics

More from Device Area

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By Marion Webb

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.